A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This open-label, single-arm, non-randomized study will evaluate the adherence and persistence
to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who
have an inadequate clinical response to non-biologic DMARDs. Patients will receive
tocilizumab 8 mg/kg as intravenous infusion once every 4 weeks in combination with
methotrexate or in case of intolerance to methotrexate as monotherapy. The anticipated time
of study treatment is 6 months. The target sample size is 20-50 patients.